GSK lifts ban on doctor payments
Several years of extra strict rules for collaborations with healthcare professionals have made it difficult for Glaxosmithkline to communicate its message. The company therefore reduces its demands in different countries, including Denmark, and will again allow doctors to receive payment for certain tasks.
The global drug group Glaxosmithkline (GSK) updates its policy for collaborations with healthcare professionals after years of being one of the companies with the most restrictive rules.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
